Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29 Category: Altai Protocol Library - Altai Oncology
Study: Multicenter, open-label, single-arm trial Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and
Study: Phase II, open-label, single-arm study Cisplatin-fit resectable cT2-T4a,cN0-N1 MIUC GC+ Durvalumab followed by surgery followed by Durvalumab maintenance Efficacy: 2-year EFS: 76% [62-85] 3-year EFS: 73% [59-83] 2-year OS:
Study: Phase Ib/II, open-label, multicenter study Recurrent or stage IV cervical cancer Arm D: Tisotumab vedotin + Carboplatin (first line, n=33); Arm E: Tisotumab + Pembrolizumab (first line, n=33); Arm
Study: Phase II, double-blind, placebo-controlled trial (MAINTAIN) Patients with HR+, HER2- MBC, whose cancer progressed during ET and CDK4/6i ET+ Ribociclib (n=60) vs. ET (n=59) Efficacy: mPFS: 5.29 vs. 2.76
Study: Single-arm, multicenter, phase II trial HER2 positive, unresectable or metastatic gastric or gastro-esophageal junction cancer, progressive disease on or after first-line therapy with a trastuzumab-containing regimen Trastuzumab-deruxtecan (n=79) Efficacy:
Study: A Phase II, Randomized, Open-label, multicenter trial Progression under first-line treatment (except for immunotherapy) of dMMR/MSI metastatic colorectal cancer Avelumab (n=65) vs SOC (n=67) Efficacy: mOS: 25.8 vs. 23.4
Study: A Phase III placebo-controlled, Randomized, Open-label trial (KEYNOTE-671) Resectable, early stage (stage II and III) NSCLC Arm A: Pembrolizumab + chemotherapyS->Pembrolizumab (n=397) Arm B: ChemotherapyS->PBO (n=400) Efficacy: mEFS: NR
Study: A Phase III, Randomized, Open-label trial (MIRASOL) Platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression Mirvetuximab soravtansine (n=227) vs SOC (n=226)
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.